Objectives: The aim of the study was to evaluate the impact of fluorescence in situ hybridization (FISH) diagnostics on the T stage in final histology specimen of patients undergoing radical nephroureterectomy (RNU) due to upper tract urothelial carcinoma (UTUC) at a large tertiary care center. Methods: We retrospectively analyzed patients who underwent RNU at our center between 2008 and 2020. Inclusion criteria were RNU due to UTUC. Urine cytologies were used for FISH analysis to detect chromosomal abnormalities. Pre-FISH group was defined as patients without access to routine preoperative urinary FISH testing (2008–2014), and FISH group was defined as patients with access to routine FISH testing. Primary outcome was T stage in final histology. Statistical analysis was performed by χ2 test and Mann-Whitney U test. Results: Out of 212 patients who underwent RNU at our center between 2008 and 2020, 155 patients were included into the final analysis. The median age was 71 (range 33–90) years, and 108 (69.7%) patients were male and 47 (30.3%) female. Age and gender were not differently distributed in both groups (age: p = 0.925; gender: p = 0.682). Organ-confined disease was found in 37/72 patients in the pre-FISH cohort and in 48/83 patients in the FISH cohort (p = 0.422). Within organ-confined disease, 18/37 patients revealed a T stage smaller than T1 in the pre-FISH cohort and 35/48 patients in the FISH cohort (p = 0.022). Conclusions: Preoperative FISH diagnostics add important information to preoperative diagnostic workup of patients with UTUC. Within organ-confined disease, a significant shift toward T stages lower than T1 is observed. Further research is required to determine the impact of this shift on survival in UTUC.

1.
Roberts
JL
,
Ghali
F
,
Aganovic
L
,
Bechis
S
,
Healy
K
,
Rivera-Sanfeliz
G
, et al.
Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology
.
Abdom Radiol
.
2019
;
44
(
12
):
3893
905
. .
2.
Roupret
M
,
Babjuk
M
,
Compérat
E
,
Zigeuner
R
,
Sylvester
RJ
,
Burger
M
, et al.
European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update
.
Eur Urol
.
2018
;
73
(
1
):
111
22
.
3.
Miyake
M
,
Tatsumi
Y
,
Fujimoto
K
,
Nagao
K
,
Sakano
S
,
Matsuyama
H
, et al.
Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study
.
Jpn J Clin Oncol
.
2016
;
46
(
12
):
1148
55
. .
4.
Hassler
MR
,
Bray
F
,
Catto
JWF
,
Grollman
AP
,
Hartmann
A
,
Margulis
V
, et al.
Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature
.
Eur Urol
.
2020
;
78
(
2
):
209
20
. .
5.
Wang
Q
,
Zhang
T
,
Wu
J
,
Wen
J
,
Tao
D
,
Wan
T
, et al.
Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China
.
BMC Urol
.
2019
;
19
(
1
):
24
. .
6.
Straub
J
,
Strittmatter
F
,
Karl
A
,
Stief
CG
,
Tritschler
S
.
Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma
.
Urol Oncol
.
2013
;
31
(
7
):
1166
70
. .
7.
Emamekhoo
H
,
Dhillon
P
,
Gopalakrishnan
D
,
Elson
P
,
Stephenson
A
,
Magi-Galluzzi
C
, et al.
Prognostic factors and risk stratification in invasive upper tract urothelial carcinoma
.
Clin Genitourin Cancer
.
2018
;
16
(
4
):
e751
60
. .
8.
Skacel
M
,
Fahmy
M
,
Brainard
JA
,
Pettay
JD
,
Biscotti
CV
,
Liou
LS
, et al.
Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology
.
J Urol
.
2003
;
169
(
6
):
2101
5
. .
9.
Su
X
,
Hao
H
,
Li
X
,
He
Z
,
Gong
K
,
Zhang
C
, et al.
Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma
.
Oncotarget
.
2017
;
8
(
16
):
26106
11
. .
10.
Reid-Nicholson
MD
,
Ramalingam
P
,
Adeagbo
B
,
Cheng
N
,
Peiper
SC
,
Terris
MK
.
The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder
.
Mod Pathol
.
2009
;
22
(
1
):
119
27
. .
11.
Edge
SB
,
Carducci
DR
,
Compton
MA
,
Fritz
CC
,
Greene
AG
.
AJCC cancer staging manual
,
Vol. 649
.
New York
:
Springer
;
2010
.
12.
Seideman
C
,
Canter
D
,
Kim
P
,
Cordon
B
,
Weizer
A
,
Oliva
I
, et al.
Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?
World J Urol
.
2015
;
33
(
9
):
1309
13
. .
13.
Taylor
J
,
Meng
X
,
Ghandour
R
,
Margulis
V
.
Advancements in the clinical management of upper tract urothelial carcinoma
.
Expert Rev Anticancer Ther
.
2019
;
19
(
12
):
1051
60
. .
14.
Yu
Q
,
Li
Y
,
Li
G
,
Li
T
,
Zeng
H
,
Yang
Z
, et al.
Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens
.
Oncol Lett
.
2016
;
12
(
1
):
183
8
. .
15.
Smith
AK
,
Stephenson
AJ
,
Lane
BR
,
Larson
BT
,
Thomas
AA
,
Gong
MC
, et al.
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management
.
Urology
.
2011
;
78
(
1
):
82
6
. .
16.
Jung
H
,
Giusti
G
,
Fajkovic
H
,
Herrmann
T
,
Jones
R
,
Straub
M
, et al.
Consultation on UTUC, Stockholm 2018: aspects of treatment
.
World J Urol
.
2019
;
37
(
11
):
2279
87
. .
17.
Cha
EK
,
Shariat
SF
,
Kormaksson
M
,
Novara
G
,
Chromecki
TF
,
Scherr
DS
, et al.
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
.
Eur Urol
.
2012
;
61
(
4
):
818
25
. .
18.
Kamat
AM
,
Karam
JA
,
Grossman
HB
,
Kader
AK
,
Munsell
M
,
Dinney
CP
.
Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity
.
BJU Int
.
2011
;
108
(
7
):
1119
23
. .
19.
Gayed
BA
,
Seideman
C
,
Lotan
Y
.
Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma
.
J Urol
.
2013
;
190
(
4
):
1181
6
. .
20.
Wang
LJ
,
Chou
WC
,
Pang
ST
,
Yang
CW
,
Chuang
CK
,
Chang
YH
, et al.
Risk stratification of upper urinary tract urothelial carcinoma patients for survival prediction: a simple summation scoring method
.
J Cancer
.
2018
;
9
(
13
):
2284
94
. .
21.
Zhai
TS
,
Jin
L
,
Feng
LM
,
Zhou
Z
,
Liu
X
,
Liu
H
, et al.
Perioperative chemotherapy on survival in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy: a population-based study
.
Front Oncol
.
2020
;
10
(
481
):
481
. .
22.
Raman
JD
,
Ng
CK
,
Scherr
DS
,
Margulis
V
,
Lotan
Y
,
Bensalah
K
, et al.
Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy
.
Eur Urol
.
2010
;
57
(
6
):
1072
9
. .
23.
Honda
Y
,
Goto
K
,
Sentani
K
,
Yasui
W
,
Ikeda
K
,
Matsubara
A
, et al.
T categorization of urothelial carcinomas of the ureter with CT: preliminary study of new diagnostic criteria proposed for differentiating T2 or lower from T3 or higher
.
AJR Am J Roentgenol
.
2015
;
204
(
4
):
792
7
. .
24.
Miyake
M
,
Owari
T
,
Hori
S
,
Nakai
Y
,
Fujimoto
K
.
Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma
.
Res Rep Urol
.
2018
;
10
:
251
61
. .
25.
Verges
DP
,
Lallas
CD
,
Hubosky
SG
,
Bagley
DH
.
Endoscopic treatment of upper tract urothelial carcinoma
.
Curr Urol Rep
.
2017
;
18
(
4
):
31
. .
26.
Cutress
ML
,
Stewart
GD
,
Wells-Cole
S
,
Phipps
S
,
Thomas
BG
,
Tolley
DA
.
Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience
.
BJU Int
.
2012
;
110
(
11
):
1608
17
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.